The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months. Why are conventional treatments so limited? Recent scientific advances point to a fundamental cause: therapeutic resistance arises not only from the intrinsic heterogeneity of tumor cells but also from a long-overlooked “tumor microenvironment (TME) ecosystem.”<\/p>\n
Within this ecosystem, resident microglia and recruited macrophages are not passive bystanders but are actively “educated” by the tumor to become pillars of immunosuppression. They construct a barrier that disables adaptive immunity, creating a paradox of “inflammation<\/a> without immunity,” in which infiltrating lymphocytes are often rendered exhausted and dysfunctional. Beyond immune dysregulation, glioma progression relies on deep interactions with non-immune components of the central nervous system<\/a>. Groundbreaking studies show that neurons form functional excitatory synapses with glioma cells, driving tumor growth through neurotransmitter release (e.g., glutamate). This activity-dependent growth embeds tumor cells within neural circuits, creating a feed-forward loop. Simultaneously, other brain cells are co-opted: reactive astrocytes enhance invasion via gap junctions and secreted factors while fostering an immunosuppressive niche; Cells of the oligodendrocyte lineage are manipulated to support tumor angiogenesis and immune evasion. Additionally, glioma-induced vascular remodeling results in a leaky and disorganized vascular network that, while fueling tumor metabolism, severely hampers drug delivery.<\/p>\n Thus, the glioma TME acts as both the central conductor of therapeutic failure and an unprecedented source of therapeutic opportunity. The old paradigm of targeting cancer cells alone is shifting toward a more nuanced strategy: disrupting neuron\u2011tumor communication and reprogramming the immune landscape from suppressive to antitumor states.<\/p>\n This review synthesizes the latest advances in decoding the multilayered glioma TME, with special emphasis on stromal-glioma crosstalk and myeloid cell plasticity, to provide a conceptual framework for next-generation therapies. It marks a fundamental shift in glioma therapeutics: the future battlefield lies in dismantling the entire tumor-supporting ecosystem, not merely eliminating malignant cells-offering new hope in the fight against this devastating disease.<\/p>\n Source:<\/p>\n Journal reference:<\/p>\n